Evidence map›Paper›PMID 25260311›Full record

ReviewBest practice & research. Clinical gastroenterology2014

Integration of genomic information in the clinical management of HCC.

Iris M Quetglas, Agrin Moeini, Roser Pinyol, Josep M Llovet

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Best practice & research. Clinical gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Translational Regulation in Hepatocellular Carcinogenesis.Drug design, development and therapy · 2021
    Review
  6. Article
  7. Review
  8. CRKII overexpression promotes theOncology letters · 2019
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Iris M QuetglasHCC Translational Research Laboratory, Barcelona Clinic Liver Cancer Group (BCLC), Liver Unit, IDIBAPS, Hospital Clínic, CIBERehd, University of Barcelona, C/Rosselló 153, 08036 Barcelona, Catalonia, Spain. Electronic address: imartinez@clinic.ub.es.
Agrin MoeiniHCC Translational Research Laboratory, Barcelona Clinic Liver Cancer Group (BCLC), Liver Unit, IDIBAPS, Hospital Clínic, CIBERehd, University of Barcelona, C/Rosselló 153, 08036 Barcelona, Catalonia, Spain. Electronic address: amoeini@clinic.ub.es.
Roser PinyolHCC Translational Research Laboratory, Barcelona Clinic Liver Cancer Group (BCLC), Liver Unit, IDIBAPS, Hospital Clínic, CIBERehd, University of Barcelona, C/Rosselló 153, 08036 Barcelona, Catalonia, Spain. Electronic address: rpinyol@clinic.cat.
Josep M LlovetHCC Translational Research Laboratory, Barcelona Clinic Liver Cancer Group (BCLC), Liver Unit, IDIBAPS, Hospital Clínic, CIBERehd, University of Barcelona, C/Rosselló 153, 08036 Barcelona, Catalonia, Spain; Mount Sinai Liver Cancer Program, Icahn School of Medicine at Mount Sinai, Mount Sinai School of Medicine, New York, NY, USA; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain. Electronic address: jmllovet@clinic.ub.es.
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESUniversitat de Barcelona · ES

Funding

Integrative genomic analysis in hepatocellular carcinomaR01DK076986 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LLOVET, JOSEP M · 2007 to 2011
$1.3M
NIDDK NIH HHS R01 DK076986
6 · The paper itself

Abstract

Molecular profiling of hepatocellular carcinoma (HCC) is enabling the advancement of novel approaches to disease diagnosis and management. Accurate prognosis prediction in HCC is specially critical. Clinical staging systems for HCC support clinical decision-making (e.g., BCLC algorithm) might be complemented by molecular-based information in the near future. Molecular signatures derived from tumour and non-tumour samples are associated with patient recurrence an outcome. Single nucleotide polymorphisms have been linked with HCC development. Next generation sequencing studies have brought to light the genomic diversity of this disease. Gens recurrently altered in HCC and susceptible to be targeted belong to signalling pathways including telomere maintenance, cell cycle, chromatin remodelling, Wnt/beta-catenin, RAS/RAF/MAPK and PI3K/AKT/mTOR pathways. Oncogenic loops are unknown but might include some of the already discovered aberrations. Despite the intratumoral heterogeneity observed in HCC tumours, studies including large number of samples can identify key genetic drivers and contribute to the development of novel treatments and a personalized medicine.

Indexed as

GenomicsCarcinoma, HepatocellularGene Expression ProfilingHumansLiver NeoplasmsMolecular Targeted TherapyBiomarkerGene signaturesHepatocellular carcinomaMolecular profilingTargeted therapies

Identifiers

PMID25260311
PMCPMC12261307
OpenAlexW1988619719

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.